Boston Scientific Current Ratio 2010-2024 | BSX
Current and historical current ratio for Boston Scientific (BSX) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Boston Scientific current ratio for the three months ending March 31, 2024 was 1.67.
| Boston Scientific Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2024-03-31 | $8.19B | $4.92B | 1.67 |
| 2023-12-31 | $6.51B | $4.93B | 1.32 |
| 2023-09-30 | $6.50B | $4.58B | 1.42 |
| 2023-06-30 | $5.89B | $4.56B | 1.29 |
| 2023-03-31 | $5.70B | $4.08B | 1.40 |
| 2022-12-31 | $5.76B | $3.80B | 1.52 |
| 2022-09-30 | $5.14B | $3.55B | 1.45 |
| 2022-06-30 | $5.08B | $3.88B | 1.31 |
| 2022-03-31 | $5.07B | $4.28B | 1.19 |
| 2021-12-31 | $6.32B | $4.27B | 1.48 |
| 2021-09-30 | $6.23B | $4.02B | 1.55 |
| 2021-06-30 | $6.76B | $4.07B | 1.66 |
| 2021-03-31 | $6.10B | $3.39B | 1.80 |
| 2020-12-31 | $6.69B | $3.68B | 1.82 |
| 2020-09-30 | $6.16B | $3.30B | 1.87 |
| 2020-06-30 | $5.80B | $3.11B | 1.87 |
| 2020-03-31 | $4.82B | $3.98B | 1.21 |
| 2019-12-31 | $4.70B | $4.87B | 0.97 |
| 2019-09-30 | $4.85B | $4.25B | 1.14 |
| 2019-06-30 | $6.33B | $4.85B | 1.31 |
| 2019-03-31 | $6.23B | $4.48B | 1.39 |
| 2018-12-31 | $4.00B | $5.26B | 0.76 |
| 2018-09-30 | $3.97B | $5.08B | 0.78 |
| 2018-06-30 | $3.93B | $4.75B | 0.83 |
| 2018-03-31 | $4.08B | $4.99B | 0.82 |
| 2017-12-31 | $3.82B | $5.65B | 0.68 |
| 2017-09-30 | $3.48B | $4.83B | 0.72 |
| 2017-06-30 | $3.22B | $4.30B | 0.75 |
| 2017-03-31 | $3.03B | $3.49B | 0.87 |
| 2016-12-31 | $3.24B | $3.59B | 0.90 |
| 2016-09-30 | $3.18B | $3.02B | 1.06 |
| 2016-06-30 | $3.33B | $3.18B | 1.05 |
| 2016-03-31 | $3.16B | $2.61B | 1.21 |
| 2015-12-31 | $3.47B | $2.43B | 1.43 |
| 2015-09-30 | $3.46B | $2.24B | 1.55 |
| 2015-06-30 | $3.77B | $1.94B | 1.95 |
| 2015-03-31 | $3.19B | $2.46B | 1.30 |
| 2014-12-31 | $3.61B | $2.85B | 1.27 |
| 2014-09-30 | $3.18B | $1.82B | 1.75 |
| 2014-06-30 | $3.21B | $1.77B | 1.81 |
| 2014-03-31 | $2.94B | $1.72B | 1.71 |
| 2013-12-31 | $3.01B | $1.82B | 1.65 |
| 2013-09-30 | $3.53B | $1.90B | 1.85 |
| 2013-06-30 | $3.50B | $2.48B | 1.41 |
| 2013-03-31 | $3.10B | $1.64B | 1.90 |
| 2012-12-31 | $3.02B | $1.77B | 1.71 |
| 2012-09-30 | $3.17B | $1.82B | 1.75 |
| 2012-06-30 | $3.11B | $1.79B | 1.73 |
| 2012-03-31 | $3.09B | $1.67B | 1.85 |
| 2011-12-31 | $3.11B | $1.81B | 1.72 |
| 2011-09-30 | $3.21B | $1.89B | 1.70 |
| 2011-06-30 | $3.15B | $1.89B | 1.66 |
| 2011-03-31 | $3.57B | $2.04B | 1.75 |
| 2010-12-31 | $3.62B | $2.61B | 1.39 |
| 2010-09-30 | $3.56B | $2.96B | 1.20 |
| 2010-06-30 | $3.99B | $3.72B | 1.07 |
| 2010-03-31 | $3.75B | $2.91B | 1.29 |
| 2009-12-31 | $4.60B | $3.02B | 1.52 |
| 2009-09-30 | $4.96B | $3.18B | 1.56 |
| 2009-06-30 | $4.80B | $2.75B | 1.74 |
| 2009-03-31 | $4.57B | $2.43B | 1.88 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $113.715B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $183.514B | 24.03 |
| Stryker (SYK) | United States | $129.352B | 30.98 |
| Medtronic (MDT) | Ireland | $103.107B | 15.43 |
| EssilorLuxottica (ESLOY) | France | $101.762B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $40.392B | 0.00 |
| Haleon (HLN) | United Kingdom | $39.132B | 28.57 |
| ResMed (RMD) | United States | $27.007B | 25.36 |
| Terumo (TRUMY) | Japan | $24.269B | 34.27 |
| Koninklijke Philips (PHG) | Netherlands | $23.059B | 18.30 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.264B | 14.22 |
| Baxter (BAX) | United States | $17.305B | 12.30 |
| Insulet (PODD) | United States | $14.411B | 63.90 |
| Demant (WILYY) | Denmark | $10.984B | 0.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.877B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.994B | 26.14 |
| BellRing Brands (BRBR) | United States | $7.556B | 35.54 |
| Lantheus Holdings (LNTH) | United States | $5.677B | 14.15 |
| GN Store Nord (GNNDY) | Denmark | $4.364B | 24.51 |
| Haemonetics (HAE) | United States | $4.251B | 20.96 |
| Perrigo (PRGO) | Ireland | $3.490B | 10.58 |
| Neogen (NEOG) | United States | $3.487B | 33.54 |
| Prestige Consumer Healthcare (PBH) | United States | $3.449B | 16.41 |
| TG Therapeutics (TGTX) | United States | $2.966B | 83.43 |
| ICU Medical (ICUI) | United States | $2.799B | 24.70 |
| Envista Holdings (NVST) | United States | $2.750B | 11.35 |
| Green Thumb Industries (GTBIF) | United States | $2.568B | 50.27 |
| Agios Pharmaceuticals (AGIO) | United States | $2.537B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.203B | 12.23 |
| LeMaitre Vascular (LMAT) | United States | $1.838B | 53.87 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.731B | 0.00 |
| Warby Parker (WRBY) | United States | $1.558B | 0.00 |
| InMode (INMD) | Israel | $1.512B | 8.04 |
| AdaptHealth (AHCO) | United States | $1.289B | 9.58 |
| Verano Holdings (VRNOF) | United States | $1.266B | 0.00 |
| Owens & Minor (OMI) | United States | $1.179B | 10.27 |
| AtriCure (ATRC) | United States | $1.013B | 0.00 |
| National Vision Holdings (EYE) | United States | $1.006B | 32.00 |
| BioLife Solutions (BLFS) | United States | $0.984B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.771B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.710B | 15.12 |
| PetIQ (PETQ) | United States | $0.656B | 21.21 |
| Evolus (EOLS) | United States | $0.654B | 0.00 |
| Surmodics (SRDX) | United States | $0.598B | 37.46 |
| VAREX IMAGING (VREX) | United States | $0.590B | 13.88 |
| Valneva SE (VALN) | France | $0.520B | 0.00 |
| ZimVie (ZIMV) | United States | $0.495B | 42.21 |
| Canopy Growth (CGC) | Canada | $0.494B | 0.00 |
| Quanterix (QTRX) | United States | $0.485B | 0.00 |
| Biote (BTMD) | United States | $0.449B | 10.33 |
| Jin Medical (ZJYL) | China | $0.432B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.417B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.312B | 10.05 |
| Cerus (CERS) | United States | $0.311B | 0.00 |
| Zynex (ZYXI) | United States | $0.274B | 37.52 |
| MacroGenics (MGNX) | United States | $0.269B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.257B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.247B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.245B | 24.31 |
| Sanara MedTech (SMTI) | United States | $0.243B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.237B | 14.90 |
| Omeros (OMER) | United States | $0.225B | 0.00 |
| High Tide (HITI) | Canada | $0.177B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.155B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.153B | 21.70 |
| TriSalus Life Sciences (TLSI) | United States | $0.151B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.148B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.140B | 67.00 |
| Quipt Home Medical (QIPT) | United States | $0.130B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.126B | 0.00 |
| Veru (VERU) | United States | $0.116B | 0.00 |
| Brainsway (BWAY) | Israel | $0.104B | 0.00 |
| InterCure (INCR) | Israel | $0.099B | 16.77 |
| Fonar (FONR) | United States | $0.099B | 10.00 |
| Cellectar Biosciences (CLRB) | United States | $0.097B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.090B | 0.00 |
| Chimerix (CMRX) | United States | $0.083B | 0.00 |
| MariMed (MRMD) | United States | $0.072B | 0.00 |
| Bright Green (BGXX) | United States | $0.061B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.059B | 3.86 |
| Safety Shot (SHOT) | United States | $0.054B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.053B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.050B | 0.00 |
| Apyx Medical (APYX) | United States | $0.049B | 0.00 |
| United-Guardian (UG) | United States | $0.042B | 15.25 |
| Cytosorbents (CTSO) | United States | $0.042B | 0.00 |
| ImmuCell (ICCC) | United States | $0.035B | 0.00 |
| Modular Medical (MODD) | United States | $0.034B | 0.00 |
| Exagen (XGN) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.022B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.022B | 0.00 |
| Agape ATP (ATPC) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.016B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.013B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.006B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |